Last reviewed · How we verify
anti-CD19 CAR T cell therapy
anti-CD19 CAR T cell therapy is a Small molecule drug developed by Miltenyi Biomedicine GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | anti-CD19 CAR T cell therapy |
|---|---|
| Sponsor | Miltenyi Biomedicine GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (PHASE2, PHASE3)
- Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (PHASE2)
- Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation (PHASE1)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Co-administration of CART22-65s and huCART19 for B-ALL (PHASE1, PHASE2)
- Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (PHASE2)
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy (PHASE2)
- NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-CD19 CAR T cell therapy CI brief — competitive landscape report
- anti-CD19 CAR T cell therapy updates RSS · CI watch RSS
- Miltenyi Biomedicine GmbH portfolio CI
Frequently asked questions about anti-CD19 CAR T cell therapy
What is anti-CD19 CAR T cell therapy?
anti-CD19 CAR T cell therapy is a Small molecule drug developed by Miltenyi Biomedicine GmbH.
Who makes anti-CD19 CAR T cell therapy?
anti-CD19 CAR T cell therapy is developed by Miltenyi Biomedicine GmbH (see full Miltenyi Biomedicine GmbH pipeline at /company/miltenyi-biomedicine-gmbh).
What development phase is anti-CD19 CAR T cell therapy in?
anti-CD19 CAR T cell therapy is in Phase 1.